Log in

CT Guided Bone Biopsy Using a Battery Powered Intraosseous Device

  • Technical Note
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

Purpose

To evaluate the feasibility of a battery powered intraosseous device to perform CT-fluoroscopy guided bone biopsy.

Methods

Retrospective analysis of 12 patients in whom bone specimen were acquired from different locations under CT-fluoroscopy guidance using the OnControl bone marrow biopsy system (OBM, Vidacare, Shavano Park, TX, USA). Data of the 12 were compared to a historic cohort in whom the specimen were acquired using the classic Jamshidi Needle, as reference needle using manual force for biopsy.

Results

Technical success was reached in 11 of 12 cases, indicated by central localisation of the needle within the target lesion. All specimen sampled were sufficient for histopathological workup. Compared to the historical cohort the time needed for biopsy decreased significantly from 13 ± 6 to 6 ± 4 min (P = 0.0001). Due to the shortened intervention time the radiation dose (CTDI) during CT-fluoroscopy was lowered significantly from 169 ± 87 to 111 ± 54 mGy × cm (P = 0.0001). Interventional radiologists were confident with the performance of the needle especially when using in sclerotic or osteoblastic lesions.

Conclusion

The OBM is an attractive support for CT-fluoroscopy guided bone biopsy which is safe tool and compared to the classical approach using the Jamshidi needle leading to significantly reduced intervention time and radiation exposure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

References

  1. Ng CS, Salisbury JR, Darby AJ et al (1998) Radiologically guided bone biopsy: results of 502 biopsies. Cardiovasc Intervent Radiol 21(2):122–128

    Article  PubMed  CAS  Google Scholar 

  2. Mankin HJ, Mankin CJ, Simon MA (1996) The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society. J Bone Joint Surg Am 78(5):656–663

    PubMed  CAS  Google Scholar 

  3. Rimondi E, Staals EL, Errani C et al (2008) Percutaneous CT-guided biopsy of the spine: results of 430 biopsies. Eur Spine J 17(7):975–981

    Article  PubMed  Google Scholar 

  4. Bickels J, Jelinek JS, Shmookler BM et al (1999) Biopsy of musculoskeletal tumors. Current concepts. Clin Orthop Relat Res 212–9 pp

  5. Puri A, Shingade VU, Agarwal MG et al (2006) CT-guided percutaneous core needle biopsy in deep seated musculoskeletal lesions: a prospective study of 128 cases. Skeletal Radiol 35(3):138–143

    Article  PubMed  CAS  Google Scholar 

  6. Cohen SC, Gore JM (2008) Evaluation of a powered intraosseous device for bone marrow sampling. Anticancer Res 28(6B):3843–3846

    PubMed  Google Scholar 

  7. Reed LJ, Raghupathy R, Strakhan M et al (2011) The oncontrol bone marrow biopsy technique is superior to the standard manual technique for hematologists-in-training: a prospective, randomized comparison. Hematol Rep 3(3):e21

    Article  PubMed  Google Scholar 

  8. Miller LJ, Philbeck TE, Montez DF et al (2011) Powered bone marrow biopsy procedures produce larger core specimens, with less pain, in less time than with standard manual devices. Hematol Rep 3(1):e8

    Article  PubMed  Google Scholar 

  9. Swords RT, Anguita J, Higgins RA et al (2011) A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsy. J Clin Pathol 64(9):809–813

    Article  PubMed  Google Scholar 

  10. Espinosa LA, Jamadar DA, Jacobson JA et al (2008) CT-guided biopsy of bone: a radiologist’s perspective. AJR Am J Roentgenol 190(5):W283–W289

    Article  PubMed  Google Scholar 

  11. Sacks D, McClenny TE, Cardella JF et al (2003) Society of interventional radiology clinical practice guidelines. J Vasc Interv Radiol 14(9 Pt 2):S199–S202

    Article  PubMed  Google Scholar 

  12. Campanacci M, Mercuri M, Gamberini G (1995) Biopsy. Chir Organi Mov 80(2):113–123

    PubMed  CAS  Google Scholar 

  13. Welker JA, Henshaw RM, Jelinek J et al (2000) The percutaneous needle biopsy is safe and recommended in the diagnosis of musculoskeletal masses. Cancer 89(12):2677–2686

    Article  PubMed  CAS  Google Scholar 

  14. Hau A, Kim I, Kattapuram S et al (2002) Accuracy of CT-guided biopsies in 359 patients with musculoskeletal lesions. Skeletal Radiol 31(6):349–353

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that there are no conflicts of interest to disclose which are related directly or indirectly to the subject of the manuscript. Any other conflict of interest: Dr. med. Dirk Schnapauff: Travel grants from C.R. BARD; Dr. med. Tim Marnitz: Nothing to disclose; Dr. med. Patrick Freyhardt: Travel grants from C.R. BARD; Dr. med. Federico Collettini: Nothing to disclose; Dr. med. Kerstin Hartwig: Nothing to disclose; Dr. med. Korinna Jöhrens: Nothing to disclose. Prof. Dr. med. Bernd Hamm: Irregular funds to the Department of Radiology, not personally to Prof. Hamm, from the following companies and institutions: 1. Abbott; 2. Actelion Pharmaceuticals; 3. Bayer Schering Pharma; 4. Bayer Vital; 5. BRACCO Group; 6. Bristol-Myers Squibb; 7. Charité research organisation GmbH; 8. Deutsche Krebshilfe; 9. Dt. Stiftung für Herzforschung; 10. Essex Pharma; 11. EU Programmes; 12. Fibrex Medical Inc.; 13. Focused Ultrasound Surgery Foundation; 14. Fraunhofer Gesellschaft; 15. Guerbet; 16. INC Research; 17. InSightec Ltd.; 18. IPSEN Pharma; 19. Kendle/ MorphoSys AG; 20. Lilly GmbH; 21. Lundbeck GmbH; 22. MeVis Medical Solutions AG; 23. Nexus Oncology; 24. Novartis; 25. Parexel CRO Service; 26. Perceptive; 27. Pfizer GmbH; 28. Philipps; 29. sanofis-aventis S.A; 30. Siemens; 31. Spectranetics GmbH; 32. Terumo Medical Corporation; 33. TNS Healthcare GMbH; 34. Toshiba; 35. UCB Pharma; 36. Wyeth Pharma; 37. Zukunftsfond Berlin (TSB); 38. Amgen; 39. AO Foundation; 40. BARD; 41. BBraun (Sponsoring eines Workshops); 42. Boehring Ingelheimer; 43. Brainsgate; 44. PPD (CRO); 45. CELLACT Pharma; 46. Celgene; 47. CeloNova BioSciences; 48. Covance; 49. DC Devices, Inc. USA; 50. Ganymed; 51. Gilead Sciences; 52. Glaxo Smith Kline; 53. ICON (CRO); 54. Jansen; 55. LUX Biosciences; 56. MedPass (CRO); 57. Merck; 58. Mologen; 59. Nuvisan; 60. Pluristem; 61. Quintiles (CRO); 62. Roche; 63. Schumacher GmbH (Sponsoring eines Workshops); 64. Seattle Genetics; 65. Symphogen; 66. TauRx Therapeutics Ltd, PD Dr. med. Thomas Kröncke: nothing to disclose. Prof. Dr. med. Bernhard Gebauer: Travel grants from Perceptive Inf./Parexel, C.R. BARD, SIR-Tex Medical, AGA Amplatzer/St. Jude Medical, Cook, Angiodynamics/RITA, Bayer/Schering.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dirk Schnapauff.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schnapauff, D., Marnitz, T., Freyhardt, P. et al. CT Guided Bone Biopsy Using a Battery Powered Intraosseous Device. Cardiovasc Intervent Radiol 36, 1405–1410 (2013). https://doi.org/10.1007/s00270-013-0617-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-013-0617-z

Keywords

Navigation